Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China. A multi-center, prospective, open-label, 12-week surveillance was...

Full description

Bibliographic Details
Main Authors: Haishan Wu, Xijin Wang, Xuejun Liu, Hong Sang, Qijing Bo, Xiaodong Yang, Zhiyuan Xun, Keqing Li, Ruiling Zhang, Meijuan Sun, Duanfang Cai, Huaili Deng, Guijun Zhao, Juhong Li, Xianglai Liu, Guilai Zhan, Jindong Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Psychiatry
Subjects:
blonanserin
safety
effectiveness
post-marketing surveillance
schizophrenia
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2022.935769/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2022.935769/full

Similar Items